Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Virano Therapeutics

Ownership
Private
Employees
~10
Therapeutic Areas
OncologyRare Diseases
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Gene therapyimmune modulating small molecules (VEPOs™)combination products

Virano Therapeutics General Information

Developing proprietary molecules that temporarily dampen the immune system to give virus-based cancer therapies a greater chance to take hold and fight cancer cells[4]

Contact Information

Website
https://www.viranotx.com/
Primary Industry
Biotech
Corporate Office
Toronto and Ottawa, Ontario
Canada

Drug Pipeline

VSVΔ51
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Virano Therapeutics's pipeline data

Book a demo

Key Partnerships

Partnerships with global gene therapy players mentioned but not specified[2]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Virano Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Virano Therapeutics's complete valuation and funding history, request access »

Virano Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals